Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer

被引:5
|
作者
Harada, Toshiyuki [1 ]
Imai, Hisao [2 ,3 ]
Fumita, Soichi [4 ]
Noriyuki, Toshio [5 ]
Gamoh, Makio [6 ]
Okamoto, Masaharu [7 ]
Akashi, Yusaku [4 ]
Kizawa, Yoshiyuki [8 ]
Tokoro, Akihiro [9 ,10 ]
机构
[1] JCHO Hokkaido Hosp, Ctr Resp Dis, Sapporo, Hokkaido, Japan
[2] Gunma Prefectural Canc Ctr, Div Resp Med, Gunma, Japan
[3] Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Hidaka, Saitama, Japan
[4] Kindai Univ, Dept Med Oncol, Nara Hosp, Nara, Japan
[5] Onomichi Gen Hosp, Dept Surg, Onomichi, Hiroshima, Japan
[6] Osaki Citizen Hosp, Dept Med Oncol, Osaki, Miyagi, Japan
[7] Shionogi & Co Ltd, Med Affairs, Osaka, Japan
[8] Kobe Univ, Grad Sch Med, Dept Palliat Med, Kobe, Hyogo, Japan
[9] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Psychosomat Internal Med, Sakai, Osaka, Japan
[10] Natl Hosp Org Kinki Chuo Chest Med Ctr, Support & Palliat Care Team, Osaka, Japan
关键词
Cancer pain; GI cancer; Observational study; Opioid-induced constipation; OIC-J; VALIDATION; MANAGEMENT;
D O I
10.1007/s10147-020-01790-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Constipation is a common side effect of opioid therapy. An observational study of opioid-induced constipation (OIC) in Japanese patients with cancer (OIC-J) included 212 patients with various tumor types. This post hoc analysis of OIC-J evaluated a subgroup of patients with gastrointestinal (GI) cancer. Methods Patients were aged >= 20 years, starting strong opioid therapy, had an ECOG PS of <= 2, and must have had >= 3 bowel movements during the week before enrollment. OIC was evaluated for 2 weeks after opioid initiation using the Rome IV diagnostic criteria for colorectal disorders, as well as physician's diagnosis, number of spontaneous bowel movements, Bowel Function Index score, and patient's self-assessment. Relationships between baseline characteristics and OIC incidence, and the effects of OIC on quality of life (QOL) were also explored. Results Fifty patients from OIC-J who had GI cancer [colon (50%), stomach (28%), and esophageal (22%)] were included. OIC incidence varied by which diagnostic criteria were used (46.0-62.0%) and occurred rapidly after initiating opioid therapy. The use of prophylactic laxatives reduced the overall incidence rate of OIC from 71.0% to 47.4%. No baseline characteristics, except comorbidities, were associated with OIC incidence. Change from baseline to day 15 in PAC-SYM total score was significantly greater for patients with OIC versus those without OIC (0.188 versus -0.362;P = 0.0011). Conclusions This post hoc analysis suggests that OIC occurs rapidly in patients with GI cancer after initiating opioid therapy, and negatively impacts QOL. Early and effective intervention strategies may be particularly useful in this group. Additional Information Coauthor Makio Gamoh is deceased.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 50 条
  • [21] Naloxegol for patients with cancer pain diagnosed with opioid induced constipation (OIC): NACASY observational study.
    Davies, Andrew
    Tack, Jan
    Fernandez, Ana
    Chambers, Jonathan
    Luis Sanz, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Fentanyl, Morphine, and Opioid-Induced Constipation in Patients with Cancer-Related Pain
    Ghoshal, Arunangshu
    INDIAN JOURNAL OF PALLIATIVE CARE, 2020, 26 (04) : 535 - 536
  • [23] Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study
    Tokoro, Akihiro
    Imai, Hisao
    Fumita, Soichi
    Harada, Toshiyuki
    Noriyuki, Toshio
    Gamoh, Makio
    Akashi, Yusaku
    Sato, Hiroki
    Kizawa, Yoshiyuki
    CANCER MEDICINE, 2019, 8 (10): : 4883 - 4891
  • [24] Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study
    Masanori Mori
    Yongli Ji
    Santosh Kumar
    Takamaru Ashikaga
    Steven Ades
    International Journal of Clinical Oncology, 2017, 22 : 397 - 404
  • [25] Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study
    Mori, Masanori
    Ji, Yongli
    Kumar, Santosh
    Ashikaga, Takamaru
    Ades, Steven
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (02) : 397 - 404
  • [26] Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients.
    Harada, Toshiyuki
    Katakami, Nobuyuki
    Murata, Toru
    Shinozaki, Katsunori
    Tsutsumi, Masakazu
    Yokota, Takaaki
    Arai, Masatsugu
    Suzuki, Yura
    Narabayashi, Masaru
    Boku, Narikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Opioid-induced Neurotoxicity in Patients with Cancer Pain
    Mercadante, Sebastiano
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (10) : 1367 - 1377
  • [28] Opioid-induced Neurotoxicity in Patients with Cancer Pain
    Sebastiano Mercadante
    Current Treatment Options in Oncology, 2023, 24 : 1367 - 1377
  • [29] Naloxegol for Treating Opioid-Induced Constipation n Patients with Non-Cancer Pain
    Shoop, Corie
    Hu, Yiqun
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 51 (02) : 412 - 412
  • [30] Management of Opioid-Induced Constipation in Cancer Patients Focus on Methylnaltrexone
    Gatti, Antonio
    Sabato, Alessandro Fabrizio
    CLINICAL DRUG INVESTIGATION, 2012, 32 (05) : 293 - 301